GlassScriptPhysician profile
Brian Krusemark
NPI 1659830693
$3,049.53
in general payments reported to CMS, 2019-2025
24 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $621 · 2024: $1,106 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $322.61 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $314.35 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $309.23 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $292.41 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $286.19 | 2023-2025 | |
| Novo Nordisk INC | $271.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $228.65 | 2023-2025 | |
| Inspire Medical Systems, INC. | $161.73 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.38 | 2023-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $108.65 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.34 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $67.96 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $67.42 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $58.58 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $53.95 | 2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.88 | 2024-2025 | Capvaxive, Gardasil 9, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $49.82 | 2023-2025 | Camzyos, Eliquis |
| Dexcom, INC. | $48.93 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $44.08 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $39.57 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $30.52 | 2025 | Rexulti |
| Organon LLC | $21.38 | 2024 | |
| Amgen INC. | $18.00 | 2023 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $12.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Krusemark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.